CTO-1681 by CytoAgents for Cytokine Release Syndrome (Cytokine Storm): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CTO-1681 overview

CTO-1681 is under development for the treatment of influenza A virus subtype H5N1 and H1N1 infections, COVID-19 associated cytokine release syndrome (cytokine storm) and cytokine release syndrome in oncology. The drug candidate is a small molecule, it is administered orally. It is a beraprost isomer (isomer A), which acts by targeting G-protein coupled receptor (GPCR) and nuclear factor kappa B (NF-kB). It was under development for the treatment of COVID-19 disease.

CytoAgents overview

CytoAgents is a biotechnology company that engaged in the development of innovative pharmaceutical products. The company is headquartered in United States.

For a complete picture of CTO-1681’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.